Literature DB >> 16487034

The emerging functions of UCP2 in health, disease, and therapeutics.

Gustav Mattiasson1, Patrick G Sullivan.   

Abstract

The uncoupling proteins (UCPs) are attracting an increased interest as potential therapeutic targets in a number of important diseases. UCP2 is expressed in several tissues, but its physiological functions as well as potential therapeutic applications are still unclear. Unlike UCP1, UCP2 does not seem to be important to thermogenesis or weight control, but appears to have an important role in the regulation of production of reactive oxygen species, inhibition of inflammation, and inhibition of cell death. These are central features in, for example, neurodegenerative and cardiovascular disease, and experimental evidence suggests that an increased expression and activity of UCP2 in models of these diseases has a beneficial effect on disease progression, implicating a potential therapeutic role for UCP2. UCP2 has an important role in the pathogenesis of type 2 diabetes by inhibiting insulin secretion in islet beta cells. At the same time, type 2 diabetes is associated with increased risk of cardiovascular disease and atherosclerosis where an increased expression of UCP2 appears to be beneficial. This illustrates that therapeutic applications involving UCP2 likely will have to regulate expression and activity in a tissue-specific manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487034     DOI: 10.1089/ars.2006.8.1

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  66 in total

1.  Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation.

Authors:  Wei-Jin Fang; Chun-Jiang Wang; Yang He; Yu-Lu Zhou; Xiang-Dong Peng; Shi-Kun Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

Review 2.  Mitochondrial medicine: pharmacological targeting of mitochondria in disease.

Authors:  J S Armstrong
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

Review 3.  Effects of macronutrient excess and composition on oxidative stress: relevance to diabetes and cardiovascular disease.

Authors:  Antonio Ceriello
Journal:  Curr Atheroscler Rep       Date:  2006-11       Impact factor: 5.113

4.  Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.

Authors:  Limei Liu; Jian Liu; Xiao Yu Tian; Wing Tak Wong; Chi Wai Lau; Aimin Xu; Gang Xu; Chi Fai Ng; Xiaoqiang Yao; Yuansheng Gao; Yu Huang
Journal:  Antioxid Redox Signal       Date:  2014-03-12       Impact factor: 8.401

Review 5.  The on-off switches of the mitochondrial uncoupling proteins.

Authors:  Vian Azzu; Martin D Brand
Journal:  Trends Biochem Sci       Date:  2009-12-16       Impact factor: 13.807

6.  Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats.

Authors:  Randy L Hunter; Dong-Young Choi; Stuart A Ross; Guoying Bing
Journal:  Neurosci Lett       Date:  2008-01-22       Impact factor: 3.046

Review 7.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

8.  Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease.

Authors:  Ana Navarro; Alberto Boveris
Journal:  Front Aging Neurosci       Date:  2010-09-01       Impact factor: 5.750

9.  Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice.

Authors:  Anthony R Sheets; Péter Fülöp; Zoltán Derdák; Andrea Kassai; Edmond Sabo; Nicholas M Mark; György Paragh; Jack R Wands; György Baffy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-02-21       Impact factor: 4.052

10.  The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction.

Authors:  Barry R Palmer; Courtney L Devereaux; Sukhbir S Dhamrait; Tessa J Mocatta; Anna P Pilbrow; Chris M Frampton; Lorraine Skelton; Tim G Yandle; Christine C Winterbourn; A Mark Richards; Hugh E Montgomery; Vicky A Cameron
Journal:  Cardiovasc Diabetol       Date:  2009-06-15       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.